Covered recipient · General Payments record
GEORGES AZZI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$24,246.25
260 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $12,115.00 | 5 |
| Food and Beverage | $5,303.36 | 237 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,165.00 | 1 |
| Travel and Lodging | $1,652.08 | 4 |
| Long term medical supply or device loan | $999.96 | 12 |
| Education | $10.85 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGES AZZI
NPI 1265743017 · CMS profile ID 1401680
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
FORT LAUDERDALE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- GEORGES AZZI, NPI 1265743017, CMS profile ID 1401680, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–260 of 260 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265743017?year=2024&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
260 matching records · $24,246.25 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–260 of 260.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $83.33 | 01/18/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086631187 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.94 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101225969 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3.91 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101225971 | CMS |
| PFIZER INC. | $35.12 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131128957 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.20 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093985392 | CMS |
| PFIZER INC. | $7.70 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131108094 | CMS |
| GlaxoSmithKline, LLC. | $2.00 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116491967 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.39 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144953101 | CMS |
| TAIHO ONCOLOGY, INC. | $18.34 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137934595 | CMS |
| ABBVIE INC. | $33.40 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258439 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,366,306.64 | 121 |
| PY2024 | Principal investigator | $226,847.53 | 14 |
| PY2023 | Principal investigator | $160,151.62 | 35 |
| PY2022 | Principal investigator | $146,187.26 | 26 |
| PY2021 | Principal investigator | $68,185.02 | 12 |
| PY2020 | Principal investigator | $76,614.00 | 8 |
| PY2019 | Principal investigator | $9,730.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
121 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577676 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $75,198.00 | 11/05/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807015 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,795.00 | 11/05/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807017 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150,628.20 | 11/05/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807019 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 11/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577670 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $20.98 | 11/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577672 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577674 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $511,630.33 | 10/31/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996258 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40,853.70 | 10/09/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807013 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577668 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $388,839.05 | 09/30/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996260 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223346998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347066 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347112 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347114 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.08 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347122 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $30.24 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.79 | 09/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $945.00 | 09/11/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $370.00 | 09/11/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | DS8201-793 | No dispute reported | 06/30/2026 | 1223347134 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577666 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577660 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $20.98 | 08/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577662 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 08/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 07/17/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175391863 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 07/10/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175391875 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577658 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577656 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $87.90 | 05/27/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996254 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $34.98 | 05/27/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996256 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 05/19/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175391869 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $1,537.77 | 05/16/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236530061 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577652 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577654 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,753.00 | 04/23/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807011 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31,086.90 | 04/22/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220807009 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577646 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 04/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577648 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 04/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577650 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $117.20 | 03/25/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996246 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $163.24 | 03/25/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996248 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $79.92 | 03/25/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996250 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10.64 | 03/25/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996252 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 03/14/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228863079 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577642 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577640 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $134,179.45 | 01/03/2025 | Covered Recipient Teaching Hospital Holy Cross Hospital | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185538621 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Non-covered Recipient Entity Holy Cross Health Heart And Vascular Care | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577644 |